SCI Pharmtech Stock

SCI Pharmtech EBIT

The EBIT of SCI Pharmtech (4119.TW) as of Aug 7, 2026 is 155.25 M TWD. In the previous year, EBIT was 198.29 M TWD — a change of -21.71% (lower).

EBIT

155.25 MTWD

YoY

-21.71%

Last updated:

In 2026, SCI Pharmtech's EBIT was 155.25 M TWD, a -21.71% increase from the 198.29 M TWD EBIT recorded in the previous year.

The SCI Pharmtech EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M TWD)
Date
EBIT (M TWD)
Jan 1, 2019
705.20 base
Jan 1, 2020
469.71 base
Jan 1, 2021
63.31 base
Jan 1, 2022
404.30 base
Jan 1, 2023
163.14 base
Jan 1, 2024
198.29 base
Jan 1, 2025
155.25 base
Jan 1, 2026 (e)
396.11 base
YEAREBIT (M TWD)
2026 est 396.11
2025 155.25
2024 198.29
2023 163.14
2022 404.30
2021 63.31
2020 469.71
2019 705.20
2018 516.75
2017 234.54
2016 516.46
2015 439.69
2014 295.37
2013 205.86
2012 251.85
2011 186.07
2010 212.69
2009 214.68
2008 211.26
2007 178.90
2006 42.03
Access this data via the Eulerpool API

SCI Pharmtech Revenue

SCI Pharmtech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
2.36 B TWD
705.20 M TWD
571.10 M TWD
Jan 1, 2020
2.69 B TWD
469.71 M TWD
360.12 M TWD
Jan 1, 2021
864.22 M TWD
63.31 M TWD
55.70 M TWD
Jan 1, 2022
899.74 M TWD
404.30 M TWD
308.78 M TWD
Jan 1, 2023
1.20 B TWD
163.14 M TWD
294.72 M TWD
Jan 1, 2024
1.52 B TWD
198.29 M TWD
534.68 M TWD
Jan 1, 2025
1.34 B TWD
155.25 M TWD
107.37 M TWD
Jan 1, 2026 (e)
1.41 B TWD
396.11 M TWD
116.40 M TWD

SCI Pharmtech Margins

SCI Pharmtech stock margins

The SCI Pharmtech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SCI Pharmtech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SCI Pharmtech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
39.72 %
29.94 %
24.24 %
Jan 1, 2020
47.39 %
17.47 %
13.39 %
Jan 1, 2021
24.08 %
7.33 %
6.44 %
Jan 1, 2022
32.36 %
44.94 %
34.32 %
Jan 1, 2023
29.09 %
13.55 %
24.48 %
Jan 1, 2024
26.95 %
13.01 %
35.09 %
Jan 1, 2025
23.78 %
11.55 %
7.99 %
Jan 1, 2026 (e)
23.78 %
28.09 %
8.26 %

SCI Pharmtech Stock analysis

What does SCI Pharmtech do? SCI Pharmtech Inc is a leading company in the pharmaceutical industry based in Zhejiang, China. The company was founded in 2003 and has since grown continuously. Today, the company employs over 100 employees and has become a key player in the global supply chain of pharmaceutical raw materials and intermediates. SCI Pharmtech Inc's business model is based on the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients, as well as the manufacturing of custom chemicals. The company specializes in the production and distribution process, offering its customers a comprehensive range of products that meet the highest quality and safety standards. SCI Pharmtech Inc is divided into various divisions, each specializing in specific product categories. The main divisions are API (Active Pharmaceutical Ingredients), intermediates, and custom synthesis. The API division produces active pharmaceutical ingredients for the pharmaceutical industry, which serve as the basis for drug manufacturing. The intermediates division offers pharmaceutical intermediates used in the synthesis of active pharmaceutical ingredients. The custom synthesis division provides tailored synthesis processes for customers in need of specific chemicals or intermediates. SCI Pharmtech Inc's product portfolio includes Acetamidomalonate, Carbamazepine, and Codergocrine Mesylate, among others. The company also offers custom synthesis services, involving complex chemical syntheses and innovative technologies. SCI Pharmtech Inc places great emphasis on quality and safety. The company operates according to international standards, including GMP (Good Manufacturing Practice), ISO (International Standards Organization), and CE (Conformité Européenne). SCI Pharmtech Inc's products undergo stringent quality controls to ensure compliance with the strict regulations of global pharmaceutical regulatory authorities. Another important concern of SCI Pharmtech Inc is sustainability. The company has developed a sustainable business strategy aimed at minimizing its environmental impact and conserving resources. This includes implementing efficient production processes, reducing energy consumption and CO2 emissions, as well as promoting environmental awareness among employees and customers. Overall, SCI Pharmtech Inc is a dynamic and innovative company specializing in the production of pharmaceutical intermediates and active pharmaceutical ingredients. The company takes pride in offering high-quality products that meet the highest quality and safety standards. Through its sustainable business strategy and adherence to international standards, SCI Pharmtech Inc has achieved an excellent reputation in the pharmaceutical industry and strengthened its presence in the global market. SCI Pharmtech is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing SCI Pharmtech's EBIT

SCI Pharmtech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of SCI Pharmtech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

SCI Pharmtech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in SCI Pharmtech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about SCI Pharmtech stock

EBIT of SCI Pharmtech is 155.25 M TWD in 2026.

EBIT of SCI Pharmtech changed from 198.29 M TWD to 155.25 M TWD, representing a -21.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT SCI Pharmtech since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's SCI Pharmtech historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — SCI Pharmtech

All Key Metrics — SCI Pharmtech